EU/3/18/1990

About

On 21 March 2018, orphan designation (EU/3/18/1990) was granted by the European Commission to PharmaBio Consulting, Germany, for dimethyl fumarate for the treatment of Friedreich's ataxia.

Key facts

Active substance
dimethyl fumarate
Disease / condition
Treatment of Friedreich's ataxia
Date of decision
21/03/2018
Outcome
Positive
Orphan decision number
EU/3/18/1990

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

PharmaBio Consulting
Immentalstr. 22
79104 Freiburg
Germany
Tel. +49 761 612 94 52; +49 160 88 21 027
E-mail: info@pharma-bio.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating